author-photo

Meredith Goldwasser

Agios Pharmaceuticals

8

Papers

807

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

Statistical considerations in clinical trial design with event-free survival as the primary efficacy endpoint.

2021 Pharmaceutical Statistics
Show All
- Source
- Cite
- Save
Citations (0)
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML

2020 Blood Advances
Show All
- Source
- Cite
- Save
Citations (50)
Phase 1 Single‐ and Multiple‐Ascending‐Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG‐348, a First‐in‐Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers

2019 Clinical pharmacology in drug development
Show All
- Source
- Cite
- Save
Citations (14)
Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study

2018 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (2)
Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study

2017 Blood
Show All
- Source
- Cite
- Save
Citations (15)
Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study

2015 Blood
Show All
- Source
- Cite
- Save
Citations (52)